Volume 21, Number 8—August 2015
Dispatch
Ribavirin for Chronic Hepatitis Prevention among Patients with Hematologic Malignancies
Suzanne Tavitian, Jean-Marie Peron, Françoise Huguet, Nassim Kamar, Florence Abravanel, Odile Beyne-Rauzy, Lucie Oberic, Stanislas Faguer, Laurent Alric, Murielle Roussel, Clément Gaudin, Loïc Ysebaert, Anne Huynh, and Christian Recher
Table 2
Hepatitis E and hematologic malignancies outcomes of 26 patients observed at the University Hospital of Toulouse, France, 2003–2014*
| Characteristic | Acute leukemia, n = 9 | Indolent NHL, n = 8 | Aggressive NHL, n = 3 | Myeloma, n = 3 | Others, n = 3 |
|---|---|---|---|---|---|
| Chronic hepatitis | 2 (22) | 2 (25) | 1 (33.5) | 1 (33.5) | 0 |
| Ribavirin | 3 (33.3) | 4 (50) | 2 (66.5) | 1 (33.5) | 2 (66.5) |
| HEV clearance | 8 (89) | 7 (87.5) | 3 (100) | 3 (100) | 3 (100) |
| Postponed chemo/SCT | 3 (33.3) | 2 (25) | 0 | 0 | 0 |
| Hematologic complete response | 5 (55.5) | 7 (87.5) | 2 (66.5) | 0 | 1 (33.5) |
| Follow-up period, mo (range) | 4.2 (0.9–51.7) | 23.1 (5.6–105) | 13.1 (3–29.1) | 27 (12.8–83) | 8.4 (1.5–10) |
| Deaths | 4 (44.5) | 1 (12.5) | 1 (33.3) | 1 (33.3) | 1 (33.3) |
*Values are no. (%) patients except as indicated. NHL, non-Hodgkin lymphoma; SCT, stem cell transplantation.
Page created: July 15, 2015
Page updated: July 15, 2015
Page reviewed: July 15, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.